The Journal of Cancer Metastasis and Treatment (JCMT) is an international, peer-reviewed, open-access journal dedicated to advancing research on cancer progression, metastasis, and therapeutic strategies. The journal publishes high-quality basic, translational, and clinical studies across solid and hematologic malignancies, with a particular emphasis on metastasis-driven disease biology and management.
JCMT aims to bridge fundamental discoveries with clinical applications to accelerate innovation and improve outcomes for patients with advanced cancer.
Core areas of interest include:
- Cancer biology and progression: Molecular, cellular, and genetic mechanisms underlying tumor initiation, evolution, and metastatic dissemination
- Metastasis research: Biology of metastatic spread, tumor microenvironment interactions, and strategies for metastasis prevention and intervention
- Therapeutic approaches: Systemic therapies (chemotherapy, targeted therapy, immunotherapy), radiotherapy, and surgical management of primary and metastatic disease
- Clinical outcomes and prevention: Epidemiology, risk assessment, and strategies for early detection and prevention of cancer progression
Interdisciplinary and emerging areas are strongly encouraged, including:
- Bioinformatics and computational biology for biomarker and therapeutic target discovery
- Systems and multi-omics approaches to tumor heterogeneity and microenvironment dynamics
- Precision oncology and personalized medicine
- Immunotherapy innovations (e.g., checkpoint blockade, cell-based therapies, cancer vaccines)
- Nanotechnology and advanced drug delivery systems
- Biomedical engineering and novel diagnostic or minimally invasive technologies
JCMT welcomes a broad range of article types, including Original Articles, Reviews, Systematic Reviews, Meta-Analyses, Technical Notes, Commentaries, Editorials, Perspectives, and Letters to the Editor.
Mission:
By integrating fundamental metastasis research with state-of-the-art basic and clinical advances, JCMT seeks to accelerate scientific and clinical progress, improve survival, and enhance the quality of life for patients with metastatic cancer.
